A Phase 2, Open-label, Multiple Cohort, Single-arm, Multi-center Trial to Determine the Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-cell Acute Lymphoblastic Leukemia.

Trial Profile

A Phase 2, Open-label, Multiple Cohort, Single-arm, Multi-center Trial to Determine the Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-cell Acute Lymphoblastic Leukemia.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs JCAR 015 (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Acronyms ORBIT
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2017 According to a Juno Therapeutics media release, the company has made a strategic decision to cease development of JCAR015.
    • 01 Mar 2017 According to a Juno Therapeutics media release, status changed from not yet recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top